chevron_leftBack
As of 18 June 2026, Anebulo Pharmaceuticals, Inc. has a market cap of $14.68M USD, ranking #39181 globally and #5164 in the United States.
It ranks #3504 in the Healthcare sector, and #686 in the Biotechnology industry.
Key Stats
Market Cap
$14.68MUSD
Enterprise Value
$8.56MUSD
Net Income (TTM)
-$7.98MUSD
PB Ratio
2.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Cunningham
open_in_new
Employees
3
Founded
2020
IPO
07 May 2021
Website
anebulo.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -16% | -24% | -67% | -85% | -87% | -71% |
News
Loading...
ANEB Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ANEB
Anebulo Pharmaceuticals Inc
ISIN: US0345691036
Shares Out.:
Shares Outstanding:
40.785M1
Shares Float:
24.252M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.3600 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
1M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
1M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
188K%
|
-
|
|
NYSE: IQV
|
$26.3B
179K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
170K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
123K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$48.06B
327K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.7B
304K%
68.19T KRW
|
35.5
|
|
SIX: LONN
|
$42.51B
289K%
33.71B CHF
|
37.2
|
|
ASX: CSL
|
$42.44B
289K%
60.27B AUD
|
29.3
|
|
KRX: 068270
|
$28.03B
191K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
175K%
|
-
|
chevron_leftBack